IL251759B - Compositions and methods for treating insomnia - Google Patents

Compositions and methods for treating insomnia

Info

Publication number
IL251759B
IL251759B IL251759A IL25175917A IL251759B IL 251759 B IL251759 B IL 251759B IL 251759 A IL251759 A IL 251759A IL 25175917 A IL25175917 A IL 25175917A IL 251759 B IL251759 B IL 251759B
Authority
IL
Israel
Prior art keywords
preparations
methods
treating insomnia
insomnia
treating
Prior art date
Application number
IL251759A
Other languages
English (en)
Hebrew (he)
Other versions
IL251759A0 (en
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL251759A0 publication Critical patent/IL251759A0/en
Publication of IL251759B publication Critical patent/IL251759B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL251759A 2014-10-23 2017-04-18 Compositions and methods for treating insomnia IL251759B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Publications (2)

Publication Number Publication Date
IL251759A0 IL251759A0 (en) 2017-06-29
IL251759B true IL251759B (en) 2021-01-31

Family

ID=55761025

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251759A IL251759B (en) 2014-10-23 2017-04-18 Compositions and methods for treating insomnia

Country Status (14)

Country Link
US (3) US10188652B2 (enExample)
EP (1) EP3209298B1 (enExample)
JP (1) JP6659681B2 (enExample)
KR (1) KR102444608B1 (enExample)
CN (1) CN107810006B (enExample)
AU (1) AU2015336463B2 (enExample)
BR (1) BR112017007063A2 (enExample)
CA (1) CA2964504C (enExample)
ES (1) ES2843952T3 (enExample)
IL (1) IL251759B (enExample)
MX (1) MX376164B (enExample)
RU (1) RU2703297C2 (enExample)
SG (2) SG11201703064WA (enExample)
WO (1) WO2016063995A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6659681B2 (ja) 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法
WO2017197160A1 (en) * 2016-05-12 2017-11-16 Eisai R&D Management Co., Ltd. Methods of treating circadian rhythm sleep disorders
CN115350192B (zh) * 2016-08-10 2025-05-13 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
JP7179049B2 (ja) * 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
CN113660934A (zh) 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
CN114096251A (zh) * 2019-06-26 2022-02-25 卫材R&D管理有限公司 用于治疗睡眠问题的莱博雷生
CA3154321A1 (en) * 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
BR112022012246A2 (pt) 2019-12-20 2022-08-30 Eisai R&D Man Co Ltd Uso de lemborexant para tratar insônia
US20230103250A1 (en) * 2020-01-16 2023-03-30 Eisai R&D Management Co., Ltd. Drug substance of lemborexant and medicinal composition comprising same
US20230134935A1 (en) * 2020-04-19 2023-05-04 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
KR20250070087A (ko) 2022-09-23 2025-05-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신경변성 질병과 관련된 신경변성의 감소 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095031A1 (en) * 2010-09-22 2012-04-19 Eisai R&D Management Co., Ltd. Cyclopropane compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
MX2007003377A (es) 2004-09-23 2007-05-10 Pfizer Prod Inc Agonistas del receptor de trombopoyetina.
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
EA200970266A1 (ru) 2006-09-11 2009-08-28 Глэксо Груп Лимитед Азабициклические соединения в качестве ингибиторов повторного поглощения моноаминов
JP2010504957A (ja) 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド 3−アザ−ビシクロ[3.1.0]ヘキサン誘導体
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
BRPI0817198A2 (pt) 2007-09-21 2015-03-17 Sanofi Aventis (ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
KR101823339B1 (ko) * 2010-02-15 2018-01-31 코닌클리케 필립스 엔.브이. 제어 채널 간섭의 완화
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
JP6659681B2 (ja) 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095031A1 (en) * 2010-09-22 2012-04-19 Eisai R&D Management Co., Ltd. Cyclopropane compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAOLO BETTICA ET AL, PHASE I STUDIES ON THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SB-649868, A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST, 5 July 2011 (2011-07-05) *

Also Published As

Publication number Publication date
WO2016063995A1 (en) 2016-04-28
CA2964504C (en) 2022-08-23
ES2843952T3 (es) 2021-07-21
KR20170068478A (ko) 2017-06-19
US20190201399A1 (en) 2019-07-04
MX376164B (es) 2025-03-07
KR102444608B1 (ko) 2022-09-20
EP3209298A1 (en) 2017-08-30
EP3209298A4 (en) 2018-06-20
CA2964504A1 (en) 2016-04-28
US20200268754A1 (en) 2020-08-27
JP6659681B2 (ja) 2020-03-04
SG10202007759RA (en) 2020-09-29
CN107810006B (zh) 2021-03-30
US11026944B2 (en) 2021-06-08
IL251759A0 (en) 2017-06-29
US10188652B2 (en) 2019-01-29
BR112017007063A2 (pt) 2018-02-14
MX2017004950A (es) 2018-01-16
AU2015336463B2 (en) 2020-06-18
JP2017531683A (ja) 2017-10-26
RU2017112308A3 (enExample) 2019-05-08
SG11201703064WA (en) 2017-05-30
RU2703297C2 (ru) 2019-10-16
AU2015336463A1 (en) 2017-05-04
EP3209298B1 (en) 2020-12-02
US20170252342A1 (en) 2017-09-07
US10702529B2 (en) 2020-07-07
CN107810006A (zh) 2018-03-16
RU2017112308A (ru) 2018-11-26

Similar Documents

Publication Publication Date Title
IL280209A (en) Compositions and methods for the treatment of meibomian gland dysfunction
IL282570B (en) Methods and devices for treating pulmonary edema
IL296080B1 (en) Method for treating cancer
IL282372A (en) Haploid induction compositions and methods for use therefor
IL266458A (en) Equipment and methods for treating objects
IL258955A (en) Compositions and methods for treatment of cancer
IL251759B (en) Compositions and methods for treating insomnia
IL257105A (en) Modified cells and methods of therapy
IL258931A (en) Therapeutic compounds and methods
IL255261A0 (en) Methods for treating cancer
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
IL251215B (en) Cannabinoid composition and method for treating pain
IL255615A (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
BR112016027102A2 (pt) método e aparelho
HUE054673T2 (hu) Rák kezelésére szolgáló eljárások és készítmények
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
IL246607B (en) Improved cell compositions and methods for cancer therapy
PL3393468T3 (pl) Metody leczenia niedoboru odporności
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
IL268570B (en) Oligonucleotide compositions and methods of making the same
EP3302207A4 (en) Surface treatment apparatuses and methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed